QIAGEN Board Member Makes $2 Million Open-Market Share Purchase

The latest announcement is out from Qiagen ( (QGEN) ).

QIAGEN N.V. disclosed that Mark Stevenson, a member of its administrative or supervisory body, purchased common shares of the company on the open market. The transaction, executed on May 12, 2026 on the NYSE, amounted to approximately $2.03 million at a price of $33.79 per share, signaling insider confidence that may be closely watched by investors and market participants.

This purchase adds to transparency requirements under market abuse regulations and highlights ongoing executive engagement with QIAGEN’s equity. The sizable volume and listing across multiple exchanges may draw attention from both European and U.S. shareholders assessing governance signals and potential alignment of management interests with long-term investor value.

The most recent analyst rating on (QGEN) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

QIAGEN N.V. is a Netherlands-based life sciences company that develops and supplies sample and assay technologies for molecular diagnostics, applied testing, pharmaceutical research, and academic research, with its shares traded on major European exchanges, the NYSE and Swiss markets.

Average Trading Volume: 1,983,821

Technical Sentiment Signal: Sell

Current Market Cap: $6.94B

For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.